MENLO PARK, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today
announced financial results for its second quarter ended June 30, 2017.
Product, service and other revenue for the second quarter of 2017 increased by 17% to $20.1 million, compared to $17.2 million
for the second quarter of 2016. Total revenue for the second quarter of 2017 was $20.1 million, compared to $20.7 million for the
second quarter of 2016. Total revenue for the second quarter of 2016 included $3.6 million of contractual revenue, whereas the
second quarter of 2017 included no contractual revenue.
Gross profit for the second quarter of 2017 was $8.0 million, resulting in a gross margin of 39.9%. Gross profit for the
second quarter of 2016 was $10.6 million, resulting in a gross margin of 51.3%. This included $3.6 million of contractual revenue
at 100% gross margin. Excluding this contractual revenue and related margin, adjusted gross margin for the second quarter of 2016
would have been 41.1%. Adjusted gross margin is not meant to be considered in isolation or as a substitute for gross margin.
Adjusted gross margin is subject to limitations and should be read only in conjunction with the Company’s condensed consolidated
financial statements prepared in accordance with GAAP.
Operating expenses for the second quarter of 2017 totaled $32.4 million, compared to $28.7 million for the second quarter of
2016. Operating expenses for the second quarter of 2017 and 2016 included non-cash stock-based compensation of $4.4 million and
$4.5 million, respectively.
Net loss for the second quarter of 2017 was $25.5 million, compared to $18.5 million for the second quarter of 2016.
Cash, cash equivalents and investments, excluding restricted cash, at June 30, 2017 totaled $102.6 million, compared to $72.0
million at December 31, 2016.
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its second quarter 2017 results today at 4:30 p.m. Eastern Time.
Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330, using an Audience
Passcode of 6231-3559. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/ .
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex
problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences’ products enable: de
novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length
transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene
families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic
information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform
coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables
and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things,
statements relating to the timeline for Pacific Biosciences’ potential development of products, future uses, quality or performance
of, or benefits of using, products or technologies and other future events. You should not place undue reliance on forward-looking
statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in
some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed
or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be
found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most
recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences
undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future,
even if new information becomes available.
| Pacific Biosciences of California,
Inc. |
| Unaudited Condensed Consolidated Statement of
Operations |
| (amounts in thousands, except per share
amounts) |
| |
| |
| |
Three Months Ended
June 30,
|
|
Six Months Ended June
30, |
| |
2017
|
|
|
2016
|
|
2017
|
|
|
2016 |
| Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product revenue |
$ |
16,548 |
|
|
|
$ |
13,587 |
|
|
$ |
37,842 |
|
|
$ |
25,966 |
|
| Service and other revenue |
|
3,525 |
|
|
|
|
3,564 |
|
|
|
7,146 |
|
|
|
6,716 |
|
| Contractual revenue |
|
— |
|
|
|
|
3,596 |
|
|
|
— |
|
|
|
7,192 |
|
| Total revenue |
|
20,073 |
|
|
|
|
20,747 |
|
|
|
44,988 |
|
|
|
39,874 |
|
| Cost of Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of product revenue |
|
8,155 |
|
|
|
|
7,115 |
|
|
|
19,517 |
|
|
|
13,995 |
|
| Cost of service and other revenue |
|
3,917 |
|
|
|
|
2,988 |
|
|
|
8,533 |
|
|
|
5,731 |
|
| Total cost of revenue |
|
12,072 |
|
|
|
|
10,103 |
|
|
|
28,050 |
|
|
|
19,726 |
|
| Gross profit |
|
8,001 |
|
|
|
|
10,644 |
|
|
|
16,938 |
|
|
|
20,148 |
|
| Operating Expense: |
|
|
|
|
|
|
|
|
|
|
|
|
| Research and development |
|
16,883 |
|
|
|
|
17,522 |
|
|
|
33,854 |
|
|
|
33,883 |
|
| Sales, general and administrative |
|
15,505 |
|
|
|
|
11,192 |
|
|
|
30,770 |
|
|
|
22,900 |
|
| Total operating expense |
|
32,388 |
|
|
|
|
28,714 |
|
|
|
64,624 |
|
|
|
56,783 |
|
| Operating loss |
|
(24,387 |
) |
|
|
|
(18,070 |
) |
|
|
(47,686 |
) |
|
|
(36,635 |
) |
| Interest expense |
|
(826 |
) |
|
|
|
(795 |
) |
|
|
(1,664 |
) |
|
|
(1,574 |
) |
| Other income (expense), net |
|
(326 |
) |
|
|
|
366 |
|
|
|
(56 |
) |
|
|
358 |
|
| Net loss |
$ |
(25,539 |
) |
|
|
$ |
(18,499 |
) |
|
$ |
(49,406 |
) |
|
$ |
(37,851 |
) |
| Basic and diluted net loss per share |
$ |
(0.26 |
) |
|
|
$ |
(0.21 |
) |
|
$ |
(0.52 |
) |
|
$ |
(0.44 |
) |
| Shares used in computing basic and diluted net loss per share |
|
97,360 |
|
|
|
|
88,148 |
|
|
|
95,177 |
|
|
|
85,876 |
|
| Pacific Biosciences of California,
Inc. |
| Unaudited Condensed Consolidated Balance
Sheets |
| (amounts in thousands) |
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
June 31, |
|
December 31, |
| |
2017 |
|
2016 |
| Assets |
|
|
|
| Cash and investments |
$ |
102,596 |
|
$ |
71,978 |
| Accounts receivable |
|
9,525 |
|
|
11,421 |
| Inventory |
|
17,266 |
|
|
15,634 |
| Prepaid and other current assets |
|
3,545 |
|
|
9,978 |
| Property and equipment |
|
40,289 |
|
|
14,560 |
| Long-term restricted cash |
|
4,500 |
|
|
4,500 |
| Other long-term Assets |
|
184 |
|
|
9,813 |
| Total Assets |
$ |
177,905 |
|
$ |
137,884 |
| |
|
|
|
|
|
| Liabilities and Stockholders' Equity |
|
|
|
|
|
| Accounts payable |
$ |
6,514 |
|
$ |
8,359 |
| Accrued expenses |
|
17,840 |
|
|
16,604 |
| Deferred service revenue |
|
8,078 |
|
|
8,427 |
| Deferred rent |
|
14,599 |
|
|
19 |
| Other liabilities |
|
1,915 |
|
|
3,345 |
| Financing derivative |
|
15 |
|
|
356 |
| Notes payable |
|
13,084 |
|
|
16,106 |
| Stockholders' equity |
|
115,860 |
|
|
84,668 |
| Total Liabilities and Stockholders' Equity |
$ |
177,905 |
|
$ |
137,884 |
| |
|
|
|
|
|
Contact: Trevin Rard 650.521.8450 ir@pacificbiosciences.com
